Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @BioCentury
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioCentury
-
Gilead's O'Day on remdesivir: 'We will not get in a patent dispute'
#2019nCoV$GILDhttps://buff.ly/2S04j0CHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Initial efficacy data suggest CAR NK cells could compete with CAR Ts in blood cancers.https://buff.ly/2GXbr7J
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
After Merck spins out slower-growing businesses to focus on innovation, the company will need recent and future deals to yield fruit in order to balance its reliance on Keytruda for growth
$MRK https://buff.ly/31t3QqR pic.twitter.com/Tk8AKxjq6O
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Trump endorses Grassley-Wyden drug pricing billhttps://buff.ly/2ubuGaR
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
A big win for
@Biogen on#Tecfidera IPR, adding nearly $9B in market cap. With overhang lifted, investors now turn full attention to#Alzheimers candidate#aducanumab$BIIBhttps://buff.ly/2SpCC0hHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
FDA's Richard Pazdur supports expanded access for unapproved uses of approved drugs https://buff.ly/2GXUU3h pic.twitter.com/fdIfJPOQQy
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
EMA hopes to lower barriers to use of real-world data in regulatory decision making by creating a centralized system for integrating RWD across Europe. https://buff.ly/2GUgoho pic.twitter.com/uEML8Qo1Qb
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
.
@a16z's Vijay Pande tells@BioCentury's@_Ktktktktk the firm is investing new $750M fund in “weak AI” -- speeding and scaling up tasks humans can do -- while tech that could enable “strong AI,” which does things humans can’t do, matures.https://www.biocentury.com/article/304379Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
3/ Clinical trial delays in China could have a wide impact on the global biopharma industry. More analysis here from my colleague
@li_hongjiang -> https://www.biocentury.com/article/304370#2019nCOV#coronaviruspic.twitter.com/ZOM6XZAtP6
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
2/ICYMI: Draft report from
@WHO R&D Blueprint Clinical Trials expert group singles out Gilead's remdesivir as most promising candidate for#2019nCoV (free analysis) https://biocentury.com/article/304374 via@BioCentury$GILD#coronaviruspic.twitter.com/zxGO4I0O2l
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
We have created a free webpage that collects
@BioCentury analysis of the#coronavirus outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials. https://www.biocentury.com/coronavirus#2019nCoVpic.twitter.com/hCSzCPQit2
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Andreessen Horowitz GPs see opportunities for "weak AI," diagnostics and synthetic biology with $750M Bio Fund III
@a16zhttps://buff.ly/2ScgoyoHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
BioCentury - DARPA-funded AbCellera to develop mAbs to treat coronavirus outbreak - this is what India ought to do for which we need a genomic repository of viruses
@DBTIndiahttps://www.biocentury.com/bc-extra/company-news/2020-01-28/darpa-funded-abcellera-develop-mabs-treat-coronavirus-outbreak?utm_campaign=product&utm_medium=email&utm_source=bcextra&fullissues=true&fullissuesId=16&dateId=5e30e7fd938a3a1838199ff7&mkt_tok=eyJpIjoiTTJNNFpUZGlaamRqTkRnNSIsInQiOiJhMDZvN3Rsa0cwYjBCUlwvSWlrU0dqYjYrbzYwRGZsZFJqbWhKTEtpeDJscVZkSFNaUWJMMzN2b3c0VDFxcDVGUzlMY3RCaEFMWTNUMnVoMVRlZEE5U1ZqeEhIYTRSaTNqRDNRbWNqSE1tS0JNTGtsUTJJcUN4Y3VsTTFhc3M5WjQifQ%3D%3D …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
Read more
#coronavirus analysis from@biocentury in our free collection. https://www.biocentury.com/coronavirus https://twitter.com/krebs_matt/status/1224376763590987781 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
Delays hit clinical trials in China.
@BioCentury's@li_hongjiang speaks with Foundation's Dan Zhang and HitGen's Jin Li on#2019nCoV's impact on clinical research. https://www.biocentury.com/article/304370 For open access to all of BioCentury's#Coronavirus coverage see: https://www.biocentury.com/coronavirus pic.twitter.com/gDHRLigbA9
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
$GILD to begin enrolling patients mid-Feb in 2 trials of#remdesivir to treat#2019nCoV acute respiratory disease via@BioCentury's@LaboratoryLiz https://www.biocentury.com/article/304364 pic.twitter.com/dLlAnArZS7
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
.
@WHO draft report:$GILD's remdesivir most "promising" candidate to treat#2019nCoV, planning for trial under way.$GILD says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via@BioCenturyhttps://www.biocentury.com/article/304374Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
CEO O'Day:
$GILD has sense of "urgency" for M&A, seeking “transformative" deals a la$GLPG, as well as small- to medium-sized bolt-on takeouts. Co also working “night and day” to ramp up manufacturing for#2019nCoV therapy via@BioCentury's@LaboratoryLizhttps://www.biocentury.com/article/304375Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
BioCentury proslijedio/la je Tweet
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the
#2019nCoV outbreak. An analysis of cos most active in the region finds Roche could be most affected. via@BioCentury https://www.biocentury.com/article/304378 pic.twitter.com/UhUM5dh5VE
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.